| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| Other Sizes |
|
Description: Pentamidine Isethionate (MP-601205; MP601205) is an antimicrobial and annticancer agent that interferes with DNA biosynthesis. It exhibits antitumor and antibacterial activities by inhibiting protein tyrosine phosphatases (PTPases) and phosphatase of regenerating liver (PRL). It can be potentially used for Gambian trypanosomiasis, antimony-resistant leishmaniasis, and Pneumocystis carinii pneumonia treatment.
| ln Vitro |
Diabetes growth is inhibited in a concentration-regulated manner by pentamidine isethionate (0-10 μg/mL; 6 days; WM9, DU145, C4-2, Hey, WM480, and A549 cells) treatment [1]. It was established how harmful pentamidine isethionate is to promastigotes of the animal parasite Leishmania fanum. Pentamidine ethanesulfonate exhibited 60 times more leishmanicidal activity than cisplatin following a 72-hour period of sterility. The inhibition of DNA synthesis and cell cycle signaling in the G2/M phase is the reason why pentamidine isethionate causes more programmed cell death (PCD) than cisplatin. The calf thymus DNA (CT-DNA) undergoes a conformational change in response to pentamidine isethionate binding that is consistent with the B-->A transition. Pentamidine isethionate is equivalent to ubiquitin and causes a 6% rise in the protein's β-sheet content [2].
|
|---|---|
| ln Vivo |
Intracellular WM9 human melanoma growth is considerably inhibited by pentamidine isethionate (0.25 mg/mouse; intramuscular injection; once every 2 days; for 4 weeks; athymic nude mice) treatment [1].
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: WM9, DU145, C4-2, Hey, WM480, and A549 cells Tested Concentrations: 0-10 µg/mL Incubation Duration: 6 days Experimental Results: Growth of all six cell lines in culture Inhibited in a concentration-dependent manner, with complete inhibition of cell line growth at 10 µg/mL. |
| Animal Protocol |
Animal/Disease Models: Athymic nude mice (6 weeks old) were injected with WM9 cells [1].
Doses: 0.25 mg/mouse. Route of Administration: intramuscularinjection; once every 2 days; for 4 consecutive weeks. Experimental Results: Dramatically inhibited the growth of WM9 human melanoma in nude mice. Growth in mice. |
| References | |
| Additional Infomation |
Pentamidine isethionate appears as odorless white or almost white crystals or powder. Odor also reported as a slight butyric odor. Very bitter taste. pH (5% aqueous solution) 4.5-6.5. (NTP, 1992)
Pentamidine isethionate is an organosulfonate salt obtained by reaction of pentamidine with two equivalents of 2-hydroxyethylsulfonic acid. It has a role as a trypanocidal drug. It contains a pentamidinium(2+). Pentamidine isethionate is an antifungal prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment and prevention of Pneumocystis pneumonia (PCP). The FDA-approved uses for pentamidine isethionate depend on the dosage form of the drug. Specifically, pentamidine isethionate injection is approved to treat PCP, and pentamidine isethionate inhalant is approved to prevent PCP in people with HIV who are at high risk of developing PCP. PCP can be an opportunistic infection (OI) of HIV. Pentamidine Isethionate is a synthetic amidine derivative, Pentamidine Isethionate is an antiprotozoal and antifungal agent that appears to interact with the minor groove of AT-rich DNA regions of the pathogen genome, interfering with DNA replication and function. It is effective in the treatment of trypanosomiasis, leishmaniasis, some fungal infections, and Pneumocystis carinii pneumonia in HIV-infected patients. (NCI04) Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. See also: Pentamidine (has active moiety). |
| Molecular Formula |
C23H36N4O10S2
|
|---|---|
| Molecular Weight |
592.68
|
| Exact Mass |
592.187
|
| CAS # |
140-64-7
|
| Related CAS # |
Pentamidine;100-33-4;Pentamidine dihydrochloride;50357-45-4;Pentamidine dimesylate;6823-79-6
|
| PubChem CID |
8813
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
539.4ºC at 760mmHg
|
| Melting Point |
188-194 °C(lit.)
|
| Flash Point |
280ºC
|
| Vapour Pressure |
1.06E-11mmHg at 25°C
|
| LogP |
4.377
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
39
|
| Complexity |
493
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
YBVNFKZSMZGRAD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H24N4O2.2C2H6O4S/c20-18(21)14-4-8-16(9-5-14)24-12-2-1-3-13-25-17-10-6-15(7-11-17)19(22)23;2*3-1-2-7(4,5)6/h4-11H,1-3,12-13H2,(H3,20,21)(H3,22,23);2*3H,1-2H2,(H,4,5,6)
|
| Chemical Name |
4-[5-(4-carbamimidoylphenoxy)pentoxy]benzenecarboximidamide;2-hydroxyethanesulfonic acid
|
| Synonyms |
Pentamidine diisethionate Pentamidine isethionate salt Pentamidine Isethionate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~168.73 mM)
DMSO : ~100 mg/mL (~168.73 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.51 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.51 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.51 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6873 mL | 8.4363 mL | 16.8725 mL | |
| 5 mM | 0.3375 mL | 1.6873 mL | 3.3745 mL | |
| 10 mM | 0.1687 mL | 0.8436 mL | 1.6873 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
